BIOMARKERS AND METHODS OF USE FOR RADIATION-INDUCED LUNG INJURY
The present disclosure is directed to methods (e.g., in vitro methods) for use of nicotinamide phosphoribosyltransferase (NAMPT) as a biomarker in radiation-induced lung injury (RILI). Provided herein is an in vitro method for the diagnosis, prognosis, and/or monitoring of RILI in a human subject by providing a tissue or plasma sample from the subject and detecting the level of NAMPT therein, wherein a higher level of NAMPT in the tissue or plasma sample from the subject compared to a healthy control or a reference value is indicative for the presence of RILI in the subject. Further provided herein is a method of detecting NAMPT in a human subject by obtaining a biological sample from the subject, detecting the presence of NAMPT in the sample by contacting the sample with a capture agent that specifically binds NAMPT, and detecting binding between NAMPT and the capture agent.
1 - 34 . (canceled)
35 . A method of reducing inflammation in a human subject to address radiation-induced lung injury (RILI), the method comprising:
administering to the human subject a NAMPT inhibitor in response to a level of NAMPT in a biological sample from the human subject being higher than a healthy control or reference value.
36 . The method of claim 35 , wherein the human subject shows symptoms of RILI.
37 . The method of claim 35 , wherein the human subject is at a risk of developing RILI.
38 . The method of claim 35 , wherein the human subject is a cancer patient undergoing radiotherapy.
39 . The method of claim 35 , wherein the human subject is exposed to ionizing radiation (IR).
40 . The method of claim 35 , wherein the human subject is a cancer patient undergoing thoracic radiotherapy.
41 . The method of claim 35 , wherein the healthy control or the reference value is a level of NAMPT expression in a human subject without RILI.
42 . The method of claim 35 , wherein the biological sample is a tissue sample or a plasma sample.
43 . The method of claim 42 , wherein the sample is a tissue sample and the tissue is lung tissue, thoracic tissue, or tonsillar tissue.
44 . The method of claim 35 , wherein the NAMPT inhibitor is a polypeptide inhibitor.
45 . The method of claim 44 , wherein the NAMPT inhibitor is an anti-NAMPT antibody.
46 . The method of claim 35 , wherein the NAMPT inhibitor is a nucleic acid inhibitor.
47 . The method of claim 35 , wherein the level of NAMPT in a biological sample from the human subject is at least 2-fold higher than the healthy control or reference.
48 . The method of claim 35 , wherein the level of NAMPT in a biological sample from the human subject is at least 5-fold higher than the healthy control or reference.
49 . A method of treating lung fibrosis in a human subject in need of treatment thereof, the method comprising:
administering to the human subject a NAMPT inhibitor in response to a level of NAMPT in a biological sample from the human subject being higher than a healthy control or reference value.
50 . The method of claim 49 , wherein the biological sample is a tissue sample or a plasma sample.
51 . The method of claim 50 , wherein the sample is a tissue sample and the tissue is lung tissue, thoracic tissue, or tonsillar tissue.
52 . The method of claim 49 , wherein the NAMPT inhibitor is a polypeptide inhibitor.
53 . The method of claim 52 , wherein the NAMPT inhibitor is an anti-NAMPT antibody.
54 . The method of claim 49 , wherein the NAMPT inhibitor is a nucleic acid inhibitor.